Charlene M. Fares

Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44

Amy L. Cummings, Jaklin Gukasyan, Henry Y. Lu et al. · Nature Cancer · 2020 · 47 citations · Full text

Cancer Immunosurveillance, Non-small-cell Lung Cancer, Medicine +8

Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation

Charlene M. Fares, Timothy J. Williamson, Matthew K. Theisen et al. · JCO Clinical Cancer Informatics · 2018 · 25 citations

Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors

Curtis D. Chin, Charlene M. Fares, Maira P. Campos et al. · Modern Pathology · 2020 · 18 citations

Gene Microarray, Pd-l1 Expression, Medicine +11

Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC

Nanruoyi Zhou, Maria A. Velez, Benjamin Bachrach et al. · Lung Cancer · 2021 · 17 citations · Full text

Autoimmune Disease, Thyroid Dysfunction, Frequent Event Post-treatment +11